Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro

BACKGROUND: Advanced or metastatic renal cell carcinoma (RCC) has a poor prognosis, because it is relatively resistant to conventional chemotherapy or radiotherapy. Treatments with human interferon-α2b alone or in combination with mammalian target of rapamycin (mTOR) inhibitors have led to only a mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardillo, Thomas M, Trisal, Preeti, Arrojo, Roberto, Goldenberg, David M, Chang, Chien-Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623828/
https://www.ncbi.nlm.nih.gov/pubmed/23548153
http://dx.doi.org/10.1186/1471-2407-13-170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623828/
https://www.ncbi.nlm.nih.gov/pubmed/23548153
http://dx.doi.org/10.1186/1471-2407-13-170

Ejemplares similares